Posted by Michael Wonder on 08 Dec 2023
EnGeneIC granted FDA fast track designation for novel armed nanocell drug conjugate pancreatic cancer therapeutic
7 December 2023 - EnGeneIC has achieved a significant milestone with the granting of FDA fast track designation for its pancreatic cancer therapeutic.
EnGeneIC’s EDV therapeutic is a first in class antibody nanocell drug conjugate which also promotes a robust anti-tumour immune response.
